Altmeyer Anne 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Oct 21, 2025
Insider Transaction Report
Form 4
Altmeyer Anne
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.0001 per share
2025-10-20$4.80/sh+1,060$5,088→ 7,251 total - Sale
Common Stock, par value $0.0001 per share
2025-10-20$20.50/sh−1,060$21,730→ 6,191 total - Exercise/Conversion
Stock options (right to buy)
2025-10-20−1,060→ 4,247 totalExercise: $4.80Exp: 2032-09-26→ Common Stock (1,060 underlying)
Footnotes (3)
- [F1]This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.
- [F3]The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.